Home › Myelofibrosis › Tennessee
Myelofibrosis clinical trials in Tennessee
9 studies for Myelofibrosis are looking for participants at sites in Tennessee.
Cities in Tennessee
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
- Vanderbilt University/Ingram Cancer Center, Nashville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT06661915A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
- Tri-Star Centennial Medical Center, Nashville
- Vanderbilt University, Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT04176198A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
- Tennessee Oncology, PLLC - Investigational Drug Services, Nashville
- Tristar BMT, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT07469891A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
- Vanderbilt-Ingram Cancer Center (VICC)-Nashville, Nashville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 24, 2026 · NCT07623161Study of INCA036978 in Participants With Myeloproliferative Neoplasms
- Tristar Bmt/Tcto, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT07441694Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
- GSK Investigational Site, Nashville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 20, 2026 · NCT06517875A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
- Vanderbilt University Medical Center, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 17, 2026 · NCT06034002SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Memphis
- Massive Bio SYNERGY-AI site, Nashville
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- Tennessee Oncology, Chattanooga
- Tennessee Oncology, Nashville
- Vanderbilt University Medical Center, Nashville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2025 · NCT06479135From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.